Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8.
Larkin, J., Weber, J., Del Vecchio, M., Gogas, H., Arance, A.M., Dalle, S., et al. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. EUROPEAN JOURNAL OF CANCER, 173, 285-296 [10.1016/j.ejca.2022.06.041].
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Di Giacomo A. M.;
2022-01-01
Abstract
Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled patients per American Joint Committee on Cancer version 7 (AJCC-7) criteria. Here, we analyse long-term outcomes per AJCC-8 staging criteria compared with AJCC-7 results to inform clinical decisions for patients diagnosed per AJCC-8.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Adjuvant nivolumab versus ipilimumab 238 trial-Larkin-2022.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
1.43 MB
Formato
Adobe PDF
|
1.43 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1221042